The tweet was deleted by the author.
But we saved everything 🙂.
Eyepoint Pharmaceuticals introduced new and incremental results from four presentations at RetinaSociety2026, deepening the understanding of its DURAVYU treatment. The company unveiled additional Phase 3 LUGANO data, focused on vision, anatomical outcomes, treatment burden, and repeat dosing safety, as well as sharing mechanistic findings and real world patient insights.
This update is positioned to inform future clinical discussions and may influence broader adoption strategies for DURAVYU as more outcomes data becomes available.
View post on X Loading...
Eyepoint previously announced LUGANO Phase 3 clinical trial results and shifted its attention to the LUCIA trial for wet AMD, according to company statements. The company also sent a team to New York to attend investor conferences and connect with industry leaders as reported earlier. These developments reflect Eyepoint's ongoing efforts to advance its product pipeline and expand industry engagement.